Apellis' Empaveli Poised To Give Soliris A Run In PNH
New Drug Reaches The Market With Broad Label And Competitive Pricing
Executive Summary
The first targeted C3 therapy was approved by the US FDA for treatment-naïve patients as well as those switching from Alexion's Soliris or Ultomiris.
You may also be interested in...
Novartis’s Fabhalta Hits In Glomerulopathy But How Hard?
So far, Novartis has only reported that its Phase III trial has succeeded and investors face a wait to find out just how good the drug is.
Novartis’s Fabhalta Reaches First Stop On Regulatory Journey With PNH Nod
Novartis envisions the drug, the first oral monotherapy for PNH, as a “pipeline in a pill” that could see $3bn in peak sales, with a Phase III readout in IgAN in October and one in C3G expected this month.
Apellis Follows Wave Life By Shelving ALS Candidate After Trial Miss
Apellis’s pegcetacoplan – approved for two other indications – will not go forward in amyotrophic lateral sclerosis after a Phase II failure, two days after Wave Life made a similar call in the neurodegenerative disease.